238 related articles for article (PubMed ID: 23530091)
1. Ras inhibition boosts galectin-7 at the expense of galectin-1 to sensitize cells to apoptosis.
Barkan B; Cox AD; Kloog Y
Oncotarget; 2013 Feb; 4(2):256-68. PubMed ID: 23530091
[TBL] [Abstract][Full Text] [Related]
2. Phenotypic reversion of invasive neurofibromin-deficient schwannoma by FTS: Ras inhibition reduces BMP4/Erk/Smad signaling.
Barkan B; Kloog Y; Ehrlich M
Mol Cancer Ther; 2011 Aug; 10(8):1317-26. PubMed ID: 21632464
[TBL] [Abstract][Full Text] [Related]
3. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.
Barkan B; Starinsky S; Friedman E; Stein R; Kloog Y
Clin Cancer Res; 2006 Sep; 12(18):5533-42. PubMed ID: 17000690
[TBL] [Abstract][Full Text] [Related]
4. The inhibition of human mesangial cell proliferation by S-trans, trans-farnesylthiosalicylic acid.
Khwaja A; Sharpe CC; Noor M; Kloog Y; Hendry BM
Kidney Int; 2005 Aug; 68(2):474-86. PubMed ID: 16014024
[TBL] [Abstract][Full Text] [Related]
5. Galectin-1 inhibition induces cell apoptosis through dual suppression of CXCR4 and Ras pathways in human malignant peripheral nerve sheath tumors.
Shih TC; Fan Y; Kiss S; Li X; Deng XN; Liu R; Chen XJ; Carney R; Chen A; Ghosh PM; Lam KS
Neuro Oncol; 2019 Nov; 21(11):1389-1400. PubMed ID: 31127849
[TBL] [Abstract][Full Text] [Related]
6. NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
Park HJ; Lee SJ; Sohn YB; Jin HS; Han JH; Kim YB; Yim H; Jeong SY
Int J Oncol; 2013 Feb; 42(2):657-66. PubMed ID: 23292448
[TBL] [Abstract][Full Text] [Related]
7. The Ras inhibitor S-trans,trans-farnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance.
Gana-Weisz M; Halaschek-Wiener J; Jansen B; Elad G; Haklai R; Kloog Y
Clin Cancer Res; 2002 Feb; 8(2):555-65. PubMed ID: 11839677
[TBL] [Abstract][Full Text] [Related]
8. Ras inhibition results in growth arrest and death of androgen-dependent and androgen-independent prostate cancer cells.
Erlich S; Tal-Or P; Liebling R; Blum R; Karunagaran D; Kloog Y; Pinkas-Kramarski R
Biochem Pharmacol; 2006 Aug; 72(4):427-36. PubMed ID: 16780807
[TBL] [Abstract][Full Text] [Related]
9. Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S-farnesylthiosalicylic acid).
Blum R; Elkon R; Yaari S; Zundelevich A; Jacob-Hirsch J; Rechavi G; Shamir R; Kloog Y
Cancer Res; 2007 Apr; 67(7):3320-8. PubMed ID: 17409441
[TBL] [Abstract][Full Text] [Related]
10. Galectin-3 promotes chronic activation of K-Ras and differentiation block in malignant thyroid carcinomas.
Levy R; Grafi-Cohen M; Kraiem Z; Kloog Y
Mol Cancer Ther; 2010 Aug; 9(8):2208-19. PubMed ID: 20682656
[TBL] [Abstract][Full Text] [Related]
11. Ras inhibition enhances autophagy, which partially protects cells from death.
Schmukler E; Grinboim E; Schokoroy S; Amir A; Wolfson E; Kloog Y; Pinkas-Kramarski R
Oncotarget; 2013 Jan; 4(1):145-55. PubMed ID: 23370967
[TBL] [Abstract][Full Text] [Related]
12. Ras inhibits endoplasmic reticulum stress in human cancer cells with amplified Myc.
Yaari-Stark S; Shaked M; Nevo-Caspi Y; Jacob-Hircsh J; Shamir R; Rechavi G; Kloog Y
Int J Cancer; 2010 May; 126(10):2268-81. PubMed ID: 19998334
[TBL] [Abstract][Full Text] [Related]
13. The tumor suppressor neurofibromin confers sensitivity to apoptosis by Ras-dependent and Ras-independent pathways.
Shapira S; Barkan B; Friedman E; Kloog Y; Stein R
Cell Death Differ; 2007 May; 14(5):895-906. PubMed ID: 17096025
[TBL] [Abstract][Full Text] [Related]
14. The Ras-pathway inhibitor, S-trans-trans-farnesylthiosalicylic acid, suppresses experimental allergic encephalomyelitis.
Karussis D; Abramsky O; Grigoriadis N; Chapman J; Mizrachi-Koll R; Niv H; Kloog Y
J Neuroimmunol; 2001 Nov; 120(1-2):1-9. PubMed ID: 11694313
[TBL] [Abstract][Full Text] [Related]
15. Ras inhibition by FTS attenuates brain tumor growth in mice by direct antitumor activity and enhanced reactivity of cytotoxic lymphocytes.
Aizman E; Mor A; Levy A; George J; Kloog Y
Oncotarget; 2012 Feb; 3(2):144-57. PubMed ID: 22323550
[TBL] [Abstract][Full Text] [Related]
16. Enhancing FTS (Salirasib) efficiency via combinatorial treatment.
Wolfson E; Schmukler E; Schokoroy ST; Kloog Y; Pinkas-Kramarski R
Biol Cell; 2015 May; 107(5):130-43. PubMed ID: 25735913
[TBL] [Abstract][Full Text] [Related]
17. Functional inhibition of Ras by S-trans,trans-farnesyl thiosalicylic acid attenuates atherosclerosis in apolipoprotein E knockout mice.
George J; Afek A; Keren P; Herz I; Goldberg I; Haklai R; Kloog Y; Keren G
Circulation; 2002 May; 105(20):2416-22. PubMed ID: 12021230
[TBL] [Abstract][Full Text] [Related]
18. The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer.
Rotblat B; Ehrlich M; Haklai R; Kloog Y
Methods Enzymol; 2008; 439():467-89. PubMed ID: 18374183
[TBL] [Abstract][Full Text] [Related]
19. Suppression of survivin expression in glioblastoma cells by the Ras inhibitor farnesylthiosalicylic acid promotes caspase-dependent apoptosis.
Blum R; Jacob-Hirsch J; Rechavi G; Kloog Y
Mol Cancer Ther; 2006 Sep; 5(9):2337-47. PubMed ID: 16985068
[TBL] [Abstract][Full Text] [Related]
20. The Ras antagonist, farnesylthiosalicylic acid (FTS), inhibits experimentally-induced liver cirrhosis in rats.
Reif S; Weis B; Aeed H; Gana-Weis M; Zaidel L; Avni Y; Romanelli RG; Pinzani M; Kloog Y; Bruck R
J Hepatol; 1999 Dec; 31(6):1053-61. PubMed ID: 10604579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]